Jason's original estimate of 1 million for LYMPRO rev's was not seen as credible by most of us holding positions in AMBS, but for many others that low-ball estimate did I believe cast significant doubt over LYMPRO's mkt acceptance. I was puzzled, as were most AMBS shareholders, especially why Gerald did not challenge that estimate. It certainly seems that Jason's opinion made a difference. Hopefully, his re-calibrated estimate will trigger some buying.
I was very encouraged by his SA article, and it is widely read. Gerald and the BOD/BOA chose not to challenged Jason's original estimate for some reason. Given the fact that they are privy to all the variables involved with AMBS at any given point in time, and we clearly are not, we need to give them the benefit of the doubt. Patience, though difficult to muster at times, will in this case I believe be handsomely rewarded! LYMPRO is on deck, and with runners on 1st (Eltoprizine), 2nd (ESS) and 3rd (Manf RP ODD). Gerald, all we need is a clean single, and we're off to the big leagues!!